| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BCL5; LAZ3; BCL6A; ZNF51; ZBTB27 |
| Entrez GeneID | 604 |
| clone | 2G1B6 |
| WB Predicted band size | 78.8kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human BCL6 (AA: 147-276) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与BCL6抗体相关的代表性文献，按领域分类简要概括：
1. **文献名称**：*BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy*
**作者**：Cerchietti, L.C. et al.
**摘要**：该研究揭示了BCL6通过抑制组蛋白乙酰化酶EP300在弥漫大B细胞淋巴瘤(DLBCL)中的致癌机制，并开发了一种针对BCL6的小分子抑制剂(基于抗体表位分析)，为联合疗法提供理论依据。
2. **文献名称**：*A novel monoclonal antibody against human BCL6 protein*
**作者**：Wang, J. et al.
**摘要**：报道了一种新型抗人BCL6单克隆抗体的制备与验证，证明其在免疫组化(IHC)和流式细胞术中对BCL6蛋白的高特异性和敏感性，适用于淋巴瘤病理诊断。
3. **文献名称**：*BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt*
**作者**：Valls, E. et al.
**摘要**：通过抗体介导的BCL6染色及ChIP-seq分析，发现BCL6通过抑制SYK磷酸酶PTPROt调控B细胞受体信号通路，促进DLBCL细胞存活，为靶向BCL6的治疗策略提供新靶点。
---
**领域关联性**：以上文献涵盖BCL6抗体的应用场景，包括机制研究(文献1、3)、诊断工具开发(文献2)及治疗靶点探索(文献1、3)。如需扩展，可进一步检索BCL6抗体在生发中心形成或T细胞功能研究中的文献。
BCL6 (B-cell lymphoma 6) antibody is a critical tool in studying the BCL6 protein, a transcriptional repressor encoded by the *BCL6* gene located on chromosome 3q27. Primarily expressed in germinal center B-cells, BCL6 regulates lymphocyte differentiation, apoptosis, and immune responses by suppressing genes involved in DNA damage sensing, cell cycle arrest, and inflammatory signaling. Its dysregulation is strongly associated with B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, where chromosomal translocations or mutations lead to constitutive BCL6 overexpression, promoting oncogenesis.
BCL6 antibodies are widely used in research and diagnostics to detect BCL6 protein expression via immunohistochemistry (IHC), Western blotting, or flow cytometry. In clinical pathology, BCL6 immunostaining helps classify lymphomas and assess germinal center origin, aiding differential diagnosis. Researchers also employ these antibodies to investigate BCL6's role in normal immune function, lymphoid development, and tumorigenesis. Additionally, BCL6-targeted therapeutic strategies, such as small-molecule inhibitors disrupting BCL6-corepressor interactions, are under exploration, making BCL6 antibodies vital for validating target engagement in preclinical studies. Overall, BCL6 antibodies serve as both diagnostic biomarkers and essential reagents for unraveling BCL6's complex roles in immunity and cancer.
×
